



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application)	PATENT APPLICATION
Inventor(s): Sudeepta Aggarwal)	Art Unit: 1647
Application No.: 10/533,069)	All Ollit. 1047
Filed: January 3, 2007)	Examiner: Allen, Marianne
Title: Compositions and methods for the treatment of immune related diseases))	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP: AF

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and foreign patent, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609. Each of these references listed on the attached form PTO-1449 was cited from the related <u>JP 2004-548574 on 02/05/2010</u>.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):				
		(1)	It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d) OR		
		(2)	It is being filed within 3 months of entry of a national stage OR		
		(3)	It is being filed before the mail date of the first Office Action on the merits OR		
		(4)	It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.		
	37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filir of a national application; (2) three months beyond the date of entry of the national stage as set forth ir §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance und §1.311, then:				
		a certif	ication as specified in §1.97(e) is provided below; or		
		a fee of	f \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included with the nt of other papers filed together with this statement.		
\boxtimes	37 C.F.	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:			
	A.	a certif	ication as specified in §1.97(e) is completed below; and		
	B.	a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and			
	C.	a fee of	f \$130.00 as set forth in \$1.17(i)(1) is authorized below, enclosed, or included with the nt of other papers filed together with this statement.		
	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$130.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 50-2387 (Docket No. GNE-0269 R1 (24126.156)).				
			Respectfully submitted, Arnold & Porter LLP		
Dated:	0	4/28	By Christopher De Vry, Reg. No. 61,425		
A 11	0 D -	- I I D			
	& Porte		1		

Arnold & Porter LLP 555 Twelfth Street, NW Washington, DC 20004-1206 Tel (415) 356-3000 Fax (415) 356-3099 Customer No. 35489